Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most safety and use principles (indication for inflammatory/pruritic dermatoses, thin-layer twice daily affected-area application, limit to ≤2 consecutive weeks and ≤50 g/week, avoid occlusion, avoid face/groin/axillae and rosacea/perioral dermatitis, local adverse events, and HPA-axis/Cushing’s risk with prolonged use) are generally consistent with the provided label excerpts. However, multiple statements are either not supported by the provided label text (e.g., clinician verification wording, 'often limited to reduce risk' framing, specific effects like worsening acne/rosacea-like changes, stretch marks being explicitly listed, and detailed systemic risk factors phrased beyond label content) or are not directly matched to the label language provided.
Category Scores
Accurate Statements
Clobetasol is used to reduce inflammation and itching from steroid-responsive skin conditions.
INDICATIONS AND USAGE: “indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.”
Clobetasol can cause skin thinning (atrophy).
ADVERSE REACTIONS: “Less frequent adverse reactions were ... skin atrophy ...”
Clobetasol should be applied only to the affected areas.
DOSAGE AND ADMINISTRATION: “Apply a thin layer of clobetasol propionate ointment to the affected skin areas...”
Using clobetasol should involve using the smallest amount needed to control symptoms.
PRECAUTIONS: “only small areas should be treated at any one time due to the increased risk of HPA suppression.” (label excerpt supports limitation of area/extent in line with using small amounts/areas; exact 'smallest amount needed to control symptoms' phrasing is not verbatim but aligns with the 'small areas' and 'discontinue when control achieved' guidance).
Clobetasol should be used for the prescribed duration.
INDICATIONS AND USAGE: “Treatment beyond 2 consecutive weeks is not recommended...” and “therapy should be discontinued when control has been achieved.”
Long-term or overly extensive use of clobetasol can increase systemic steroid exposure risk, especially in children.
PRECAUTIONS: “Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically...” and “Patients receiving super-potent corticosteroids should not be treated for more than 2 weeks at a time...” plus INDICATIONS/USAGE pediatric: “Use in pediatric patients under 12 years of age is not recommended.” (provided excerpts support increased systemic absorption with extent/duration and limited pediatric use.)
If a skin problem is caused by an infection (bacterial, fungal, or viral), corticosteroids can sometimes make it worse.
PRECAUTIONS: “If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of clobetasol propionate ointment should be discontinued until the infection has been adequately controlled.” (supports that steroids may need discontinuation and infection management; provided label excerpts do not explicitly mention 'viral' worsening.)
If a skin problem is caused by an infection (bacterial, fungal, or viral), corticosteroids can sometimes mask symptoms.
PRECAUTIONS: “If concomitant skin infections are present or develop... If a favorable response does not occur promptly, use... should be discontinued...” (label excerpt does not explicitly state “mask symptoms”; this support is partial/indirect based on infection management and reassessment, not explicit masking language).
Unsupported Statements
Clobetasol is a very potent (high-strength) corticosteroid medicine.
Provided excerpts support “super-high potency” but the claim is generic; not enough provided text in excerpts to directly validate “very potent (high-strength)” wording as stated. (Label: “super-high potency corticosteroid formulations...”)
Clobetasol helps calm immune-driven inflammation in the skin.
Label excerpt describes anti-inflammatory properties but does not use 'immune-driven' phrasing.
Clobetasol can relieve itching and redness.
Label excerpt explicitly states “inflammatory and pruritic” manifestations; “redness” is not directly supported as a labeled outcome in provided text.
Clobetasol can relieve swelling.
Swelling is not explicitly stated in provided label excerpts.
Clobetasol can relieve thickened, inflamed plaques.
Plaques are not explicitly mentioned in provided label excerpts.
Clobetasol can relieve exacerbations of certain inflammatory dermatoses.
General indication is supported, but the specific phrasing about “exacerbations” is not explicitly supported in provided label excerpts.
Common clobetasol formulations include topical creams and/or ointments.
The provided label excerpts specifically reference “clobetasol propionate ointment USP, 0.05%” and do not mention creams.
Common clobetasol formulations include solutions.
The provided label excerpts do not mention solutions.
The choice of clobetasol formulation depends on the body area and skin type.
Not supported in provided excerpts.
Clobetasol use is often limited to reduce risk.
Label excerpt states specific limits (“Treatment beyond 2 consecutive weeks is not recommended” and “total dosage should not exceed 50 g/week”) but does not support the adverbial/typical-frequency claim “often limited.”
Clobetasol should be avoided on unintended sites such as the face, groin, or skin folds unless specifically directed.
Label excerpt specifically says should not be used on “face, groin, or axillae,” but does not mention “skin folds” and does not use the phrase “unintended sites ... unless specifically directed.”
Clobetasol can cause stretch marks (striae).
Provided adverse reactions list includes “striae” but not in parentheses as “stretch marks”; while conceptually aligned, the claim uses a specific synonym not explicitly present in provided label excerpt.
Clobetasol can worsen acne or rosacea-like changes.
Label excerpt includes “should not be used in the treatment of rosacea or perioral dermatitis,” but does not explicitly state “worsen acne” or “rosacea-like changes.”
Clobetasol can cause burning, irritation, or dryness where applied.
Label excerpt supports burning/irritation/itching (0.5%) and also lists “dryness” among additional local reactions; however the claim omits 'itching' and uses 'where applied'—still largely consistent. (No direct contradiction, but partially unsubstantiated as written.)
Overuse of clobetasol can increase both local and systemic risk.
Label supports increased risk with extensive area/duration and lists local adverse reactions and systemic absorption effects, but provided excerpts do not include the explicit 'both local and systemic risk' phrasing.
Local effects of clobetasol overuse can include persistent skin thinning and pigment changes.
Label excerpt includes skin atrophy and hypopigmentation, but does not explicitly connect them to “persistent” overuse or the phrase “pigment changes”.
Systemic effects of clobetasol overuse are more likely with heavy dosing, prolonged use, occlusion (covering the skin), or use over large body surface areas.
Label excerpt supports systemic absorption risk with large surface area and occlusion and limited duration, but does not explicitly phrase 'heavy dosing' and 'more likely' tied to all enumerated factors in the way stated.
Clinicians often confirm the diagnosis before prescribing a potent topical steroid, particularly for persistent rashes.
Label excerpt includes reassessment if no improvement in 2 weeks, but does not support the claim about clinicians 'often' confirming diagnosis before prescribing.
Contradictions
Low
AI Statement
Clobetasol should be avoided on unintended sites such as the face, groin, or skin folds unless specifically directed.
Label Reference
PRECAUTIONS: “should not be used on the face, groin, or axillae.” (No explicit label permission for 'unless specifically directed' in provided excerpts.)
Important Omissions
Application instructions details: label specifies “twice daily” and “rub in gently and completely,” and states “Clobetasol propionate ointment should not be used with occlusive dressings.” These are not stated in the claims list (occlusive dressings specifically).
Importance:
Moderate
Hard limits: label specifies “treatment beyond 2 consecutive weeks is not recommended” and “total dosage should not exceed 50 g/week.” The claims list includes duration but not the explicit 50 g/week limit or the “not recommended” phrasing.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-related principles align (duration limitation, affected-area use, avoidance of certain sites/conditions, local adverse reactions, systemic absorption/HPA-axis risks). However, multiple details that are material for safe use—such as explicit dosing limits (≤50 g/week), twice-daily/gentle rub-in instructions, and explicit 'no occlusive dressings'—are omitted or not clearly supported, and some statements extend beyond the provided label language.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims are not directly supported by the provided label excerpts or omit key specific safety limits (e.g., ≤50 g/week) and administration constraints (e.g., no occlusive dressings; twice-daily application).
Suggested Improvement
Restrict wording to label-supported language (e.g., explicitly state: twice daily thin layer to affected areas; limit to 2 consecutive weeks; total ≤50 g/week; discontinue when control achieved; do not use occlusive dressings; avoid face/groin/axillae and do not use for rosacea/perioral dermatitis). Remove or rephrase claims that use unsupported specifics (creams/solutions, 'immune-driven' phrasing, acne/rosacea-like worsening, stretch marks wording if not explicitly in label excerpt, and the 'often confirm diagnosis before prescribing' generalization).